,,ii #aaith ,,congress #b;d ,session ,s4 #ebig ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,august #f1 #bjbf,mr4 ,schiff 7for himself and ,mr4 ,scott of ,florida7 introduced the following bill2 which was read twice and referred to the ,committee on ,finance ,a ,,bill ,to require the ,administrator of the ,centers for ,medicare ,medicaid ,services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials4 #a4 ,short title ,this ,act may be cited as the ,american ,pharmaceutical ,security ,act4 #b4 ,report on markets for ,,api and key starting materials 7a7 ,in general ,not later than #a year after the date of enactment of this ,act1 the ,administrator of the ,centers for ,medicare ,medicaid ,services 7referred to in this section as the ,administrator7 shall submit to ,congress a report on its findings and policy recommendations regarding the use of coverage and reimbursement authorities to protect the markets of the ,united ,states and its allies for active pharmaceutical ingredients and key starting materials and reduce direct and indirect dependence on foreign adversaries 7as described in section #gia4d of title #ae1 ,code of ,federal ,regulations 7or any successor regulations77 for such ingredients and materials4 7b7 ,contents ,the report under subsection 7a7-- 7#a7 may include-- 7,a7 recommendations for price floor commitments in support of domestic manufacturing of active pharmaceutical ingredients and key starting materials to protect investments in the domestic markets of such ingredients and materials against nonmarket practices and price manipulation2 and 7,b7 recommendations that would prioritize domestically manufactured active pharmaceutical ingredients and key starting materials over foreign manufactured active pharmaceutical ingredients and key starting materials when a domestic source for the applicable ingredient or material exists2 and 7#b7 shall identify any existing gaps in data and information related to the origin and ownership of active pharmaceutical ingredients and key starting materials that the ,administrator would need to implement the recommendations included in the report4